Enanta Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2836 www.enanta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - May 28th, 2026 5:00 am
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - May 11th, 2026 3:10 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - May 11th, 2026 2:01 pm
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 3:55 pm
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? - May 7th, 2026 7:02 am
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - May 4th, 2026 5:00 am
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - Apr 13th, 2026 5:00 am
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Apr 7th, 2026 5:00 am
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Mar 30th, 2026 5:00 am
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference - Mar 15th, 2026 4:41 pm
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference - Mar 3rd, 2026 5:00 am
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Feb 12th, 2026 10:00 am
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Feb 10th, 2026 5:00 am
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Feb 9th, 2026 3:05 pm
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - Feb 9th, 2026 2:06 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - Feb 9th, 2026 2:01 pm
JPM26: Enanta outlines strategy to lead in RSV therapeutics - Jan 15th, 2026 3:39 pm
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - Jan 8th, 2026 5:00 am
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:00 am
Enanta Pharmaceuticals Insider Ups Holding During Year - Jan 1st, 2026 6:03 am